Compare Abeona Therapeutics Inc (ABEO) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs D Wave Quantum Inc — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while D Wave Quantum Inc trades at $20.54 (market cap $7.53B). The key difference: D Wave Quantum Inc is far larger — about 17.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | QBTS | |
|---|---|---|
Market Cap | $421.19M | $7.53B |
Sector | Health | Technology |
52-Week High | $7.45 | $44.78 |
52-Week Low | $4.17 | $12.98 |
Enterprise Value | $276.10M | $7.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
QBTS trades at $20.55, up 1.78% today, with a bearish technical signal despite 100% analyst buy ratings. The stock shows extreme valuation with a P/S of 583.84 and negative profitability, including a net income margin of -2,001.59% for 2026. Recent Q2 2026 earnings missed revenue and EPS estimates, though bookings surged 1,120%, highlighting growth potential amid financial strain. Cash flow trends indicate heavy investment outlays, with net cash flow turning negative in 2026.
Outlook remains speculative; the consensus price target of $38.29 offers significant upside, but high execution risks persist. Investors face volatility from unproven commercial scaling, reliance on financing, and competitive quantum computing pressures. The stock's appeal hinges on future revenue conversion from bookings, making it suitable for risk-tolerant investors betting on long-term quantum adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
